Ad hoc-Mitteilungen
• 10.07.20 Volta Finance • 10.07.20 Erytech Pharma • 10.07.20 AEVIS VICTORIA NA • 10.07.20 Agfa-Gevaert • 10.07.20 Hesse Newman Capital • 10.07.20 Volta Finance • 10.07.20 DBV Technologies • 10.07.20 BASF • 10.07.20 3,50% BASF • 10.07.20 3.375% BASF SE 05/12 •
  • Startseite
  • Aktien
  • CTI BioPharma Aktie
  • News

    • CTI BioPharma News

    1,118 € -8,29% -0,101 €
    10.07.20 08:02:07 Frankfurt | Orderbuch | Mehr Kurse »
    WKN: A2DJWX
    ISIN: US12648L6011
    US-Symbol: CTIC
    Typ: Aktie
    Jetzt für 0€ handeln

    CTI BioPharma News

      
    < Zurück < Zurück
    von 7
    Weiter > Weiter >
    < Zurück < Zurück
    von 7
    Weiter > Weiter >
    01.06.20 - PR Newswire
    CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
    CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color ...
    28.05.20 - PR Newswire
    CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4
    CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.p...
    07.05.20 - PR Newswire
    CTI BioPharma Reports First Quarter 2020 Financial Results
    CTI BioPharma Reports First Quarter 2020 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews...
    27.04.20 - PR Newswire
    CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19
    CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19 /* Style Definitions */ span.prnews_span { fon...
    08.04.20 - PR Newswire
    CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15
    CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.pr...
    12.03.20 - PR Newswire
    CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results
    CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color...
    06.03.20 - PR Newswire
    CTI BioPharma Announces Closing of Rights Offering
    CTI BioPharma Announces Closing of Rights Offering /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-...
    14.02.20 - PR Newswire
    CTI BioPharma Announces Commencement of Rights Offering
    CTI BioPharma Announces Commencement of Rights Offering /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prne...
    03.02.20 - PR Newswire
    CTI BioPharma Announces Proposed Rights Offering
    CTI BioPharma Announces Proposed Rights Offering /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-...
    03.02.20 - PR Newswire
    CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia
    CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia /* Style Definitions */ span.prnews_span ...
    09.12.19 - PR Newswire
    CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting
    CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of ...
    06.11.19 - PR Newswire
    CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting
    CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } ...
    04.11.19 - PR Newswire
    CTI BioPharma Reports Third Quarter 2019 Financial Results
    CTI BioPharma Reports Third Quarter 2019 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnew...
    01.10.19 - PR Newswire
    CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
    CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia /* Style Definitions */ span.prnew...
    01.08.19 - PR Newswire
    CTI BioPharma Reports Second Quarter 2019 Financial Results
    CTI BioPharma Reports Second Quarter 2019 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prne...
    18.07.19 - PR Newswire
    CTI BioPharma Announces Outcome From End-​of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis
    CTI BioPharma Announces Outcome From End-​of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis /* Style ...
    13.06.19 - PR Newswire
    CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
    CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black...
    29.05.19 - PR Newswire
    CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
    CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; ...
    02.05.19 - PR Newswire
    CTI BioPharma Reports First Quarter 2019 Financial Results
    CTI BioPharma Reports First Quarter 2019 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews...
    03.04.19 - PR Newswire
    CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10
    CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; col...
    13.03.19 - PR Newswire
    CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
    CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:b...
    12.03.19 - PR Newswire
    CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19
    CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; colo...
    20.02.19 - PR Newswire
    CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
    CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27 /* Style Definitions */ span.prnews_span { font-size:8pt; font-...
    11.02.19 - PR Newswire
    CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
    CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX® /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blu...
    01.02.19 - PR Newswire
    CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
    CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update /* Style Definitions */ span.prne...
    28.12.18 - PR Newswire
    CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
    CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black...
    18.12.18 - PR Newswire
    CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
    CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development /* Style Definitions */ span.prnews_span { font-size:8pt; font-...
    13.12.18 - PR Newswire
    CTI BioPharma Announces Restructuring Plan
    CTI BioPharma Announces Restructuring Plan /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-...
    26.11.18 - PR Newswire
    CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency
    CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency /* Style Definitions */ span.prnews_sp...
    01.11.18 - PR Newswire
    CTI BioPharma Reports Third Quarter 2018 Financial Results
    CTI BioPharma Reports Third Quarter 2018 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnew...
    25.10.18 - PR Newswire
    CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018
    CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews...
    01.10.18 - PR Newswire
    CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review
    CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a....
    26.09.18 - PR Newswire
    CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3
    CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color ...
    02.08.18 - PR Newswire
    CTI BioPharma Reports Second Quarter 2018 Financial Results
    CTI BioPharma Reports Second Quarter 2018 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prne...
    26.07.18 - PR Newswire
    CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018
    CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews...
    18.07.18 - PR Newswire
    CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA
    CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; ...
    09.07.18 - PR Newswire
    Results of Phase III (PIX306) Trial Evaluating Progression-​Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-​Hodgkin Lymphoma
    Results of Phase III (PIX306) Trial Evaluating Progression-​Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-​Hodgkin ...
    02.07.18 - PR Newswire
    CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
    CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib /* Style ...
    14.06.18 - PR Newswire
    CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference
    CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { c...
    06.06.18 - PR Newswire
    CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference
    CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { col...
    03.05.18 - PR Newswire
    CTI BioPharma Reports First Quarter 2018 Financial Results
    CTI BioPharma Reports First Quarter 2018 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews...
    26.04.18 - PR Newswire
    CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018
    CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { colo...
    09.03.18 - PR Newswire
    CTI BioPharma to Present at Upcoming Investor Conferences
    CTI BioPharma to Present at Upcoming Investor Conferences /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnew...
    09.03.18 - PR Newswire
    CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
    CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; col...
    07.03.18 - PR Newswire
    CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results
    CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color...
    28.02.18 - PR Newswire
    CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018
    CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black...
    14.02.18 - PR Newswire
    CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
    CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a....
    13.02.18 - PR Newswire
    CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
    CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnew...
    09.02.18 - PR Newswire
    CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock
    CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_...
    05.02.18 - PR Newswire
    CTI BioPharma Announces Launch of Follow-On Offering
    CTI BioPharma Announces Launch of Follow-On Offering /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { f...
    < Zurück < Zurück
    von 7
    Weiter > Weiter >

    Newssuche

      

    Videos

      
    10.07.20
    Börsenpunk meets Sternekoch Herrmann: McDonald's vs. Beyond Meat, Starbucks vs. Coca-Cola; Hot Stock der Woche Boston Beer
    Einfach, schnell, direkt, immer auf den Punkt - das ist der Börsenpunk. Jochen Kauper analysiert, kritisiert, ... Mehr »